



RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 31 2002

In re Application of: Zonana et al.

Art Unit: 1632

TECH CENTER 1600/2900

Application No. 09/729,658

Filed: December 4, 2000


For: HYPOHIDROTIC ECTODERMAL DYSPLASIA  
GENES AND PROTEINS

Examiner: Anne Marie Baker

Date: July 23, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 23, 2002 as First Class Mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

  
Agent for Applicant

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

**AMENDMENT**

Please enter the enclosed new Sequence listing, having pages numbered 1-58, which replaces the Sequence listing filed by Applicant on October 16, 2001, having pages numbered 1-56.

Please amend the specification as follows:

Replace the paragraph on page 3, lines 26-31, with the following:

FIG. 1 is a sequence comparison of an EDA1-II (EDA) (SEQ ID NO 2) and Tabby (Ta) (SEQ ID NO 2) proteins. Amino acid identities are indicated by an asterisk (\*). The transmembrane domain is boxed. A vertical line designates the start of the protein sequence unique to isoform II. The Gly-X-Y domain is indicated by boldface type, with the 2-amino acid interruption indicated by shadowed lettering. A blackened circle is shown above two potential N-linked glycosylation sites, and three C-terminal cysteines are indicated by underlining and boldface type.

Replace the paragraph on page 4, lines 7-11, with the following:

FIG. 4 is a comparison of the sequences of the central  $\beta$ -sheet of EDA1-II (amino acids 291-309 of SEQ ID NO 2) compared with human tumor necrosis factor (Hu TNF, SEQ ID NO